Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Jieyu Capsule for Insomnia Patients With Depressive Symptoms
NCT05764798Phase 1Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Shugan Jieyu capsule + zolpidem in Insomnia and major depressive disorder (MDD) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Insomnia Severity Index at 8 weeks. Status: unknown.
02
Drugs
Shugan Jieyu capsule + zolpidem
03
Conditions
Insomniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05764798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05764798.